Skip to main content
Premium Trial:

Request an Annual Quote

Solexa's Revenues Fall 21 Percent as Firm Winds Down MPSS Service, Launches Early-Access Sequencers

NEW YORK (GenomeWeb News) - Solexa yesterday reported a 21-percent drop in second-quarter revenues as it started winding down its MPSS service business and shipped its first early-access DNA sequencers.
 
The company reported $1.1 million in revenues for the quarter ended June 30, down from $1.4 million during the same quarter a year ago. Most of the revenue came from Solexa’s MPSS service business, and the year-over-year decline was due to reducing this service, which Solexa plans to phase out by the end of the year.
 
Solexa's revenues do not yet include proceeds from sales of DNA sequencing instruments.
 
Solexa’s R&D expenses for the quarter climbed to $5.5 million, from $4.7 million during the same period a year ago. This increase was related to higher costs for personnel and material, including building and operating several prototype instruments, as well as stock-based compensation.
 
The company’s quarterly net loss widened slightly to $9.8 million from $9.4 million in the year-ago period.
 
As of June 30, Solexa had $58.1 million in cash and cash equivalents.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.